Adaptive Bio (ADPT) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

ADPT Stock Forecast

Adaptive Bio stock forecast is as follows: an average price target of $12.33 (represents a 182.15% upside from ADPT’s last price of $4.37) and a rating consensus of 'Hold', based on 12 wall street analysts offering a 1-year stock forecast.

ADPT Price Target

The average price target for Adaptive Bio (ADPT) is $12.33 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $18.00 to $5.00. This represents a potential 182.15% upside from ADPT's last price of $4.37.

ADPT Analyst Ratings

Hold

According to 12 Wall Street analysts, Adaptive Bio's rating consensus is 'Hold'. The analyst rating breakdown for ADPT stock is 0 'Strong Buy' (0.00%), 4 'Buy' (33.33%), 7 'Hold' (58.33%), 1 'Sell' (8.33%), and 0 'Strong Sell' (0.00%).

Adaptive Bio Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Apr 04, 2024	Mark Massaro	BTIG	$5.00	$2.68	86.57%	14.42%
Dec 21, 2022	David Westenberg	Piper Sandler	$14.00	$7.09	97.46%	220.37%
Aug 17, 2022	David Westenberg	Piper Sandler	$12.00	$11.55	3.90%	174.60%
Jun 13, 2022	David Westenberg	Piper Sandler	$7.50	$6.97	7.60%	71.62%
May 06, 2022	-	Morgan Stanley	$18.00	$8.15	120.86%	311.90%

Row per page

Go to

The latest Adaptive Bio stock forecast, released on Apr 04, 2024 by Mark Massaro from BTIG, set a price target of $5.00, which represents a 86.57% increase from the stock price at the time of the forecast ($2.68), and a 14.42% increase from ADPT last price ($4.37).

Adaptive Bio Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$5.00
Last Closing Price	$4.37	$4.37	$4.37
Upside/Downside	-100.00%	-100.00%	14.42%

In the current month, the average price target of Adaptive Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Adaptive Bio's last price of $4.37. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 02, 2024	BTIG	Buy	Buy	Hold
Apr 04, 2024	BTIG	Buy	Buy	Hold
Jan 05, 2023	Scotiabank	-	Sector Outperform	Initialise
Dec 21, 2022	Piper Sandler	Neutral	Overweight	Upgrade
Dec 21, 2022	BMO Capital	-	Market Perform	Downgrade
Dec 21, 2022	Citigroup	-	Neutral	Initialise
Dec 21, 2022	Barclays	-	Equal-Weight	Initialise
Dec 21, 2022	Roth Capital	-	Buy	Initialise
Dec 21, 2022	Jefferies	-	Buy	Initialise
Dec 21, 2022	SMBC Nikko	-	Neutral	Initialise

Row per page

Go to

Adaptive Bio's last stock rating was published by BTIG on Oct 02, 2024. The company gave ADPT a "Buy" rating, the same as its previous rate.

Adaptive Bio Financial Forecast

Adaptive Bio Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$45.78M	$37.92M	$48.93M	$37.65M	$55.20M	$47.83M	$43.66M	$38.62M	$37.93M	$39.47M	$38.51M	$38.44M	$30.18M	$26.30M	$20.99M	$20.91M	$24.21M	$26.06M
Avg Forecast	$67.00M	$61.44M	$59.72M	$53.20M	$57.74M	$54.51M	$52.02M	$46.69M	$46.15M	$40.24M	$38.63M	$38.78M	$48.45M	$42.96M	$44.87M	$36.81M	$54.72M	$47.81M	$41.81M	$37.77M	$36.37M	$36.63M	$31.27M	$27.72M	$26.89M	$23.59M	$18.80M	$22.34M	$21.71M	$22.10M
High Forecast	$69.93M	$64.12M	$62.33M	$55.53M	$60.26M	$56.90M	$54.29M	$48.32M	$47.70M	$40.28M	$38.63M	$38.78M	$58.93M	$47.00M	$46.84M	$38.42M	$57.12M	$47.81M	$41.81M	$37.77M	$36.37M	$36.63M	$31.27M	$27.72M	$26.89M	$23.59M	$18.80M	$22.34M	$21.71M	$22.10M
Low Forecast	$63.25M	$57.99M	$56.37M	$50.23M	$54.50M	$51.46M	$49.10M	$45.11M	$43.31M	$40.19M	$38.63M	$38.78M	$44.15M	$40.90M	$42.36M	$34.75M	$51.66M	$47.81M	$41.81M	$37.77M	$36.37M	$36.63M	$31.27M	$27.72M	$26.89M	$23.59M	$18.80M	$22.34M	$21.71M	$22.10M
# Analysts	4	4	4	4	3	3	3	5	5	4	4	4	5	8	5	4	4	3	4	3	5	4	5	4	5	4	5	4	4	3
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.94%	0.88%	1.09%	1.02%	1.01%	1.00%	1.04%	1.02%	1.04%	1.08%	1.23%	1.39%	1.12%	1.11%	1.12%	0.94%	1.11%	1.18%

Adaptive Bio's average Quarter revenue forecast for Mar 24 based on 4 analysts is $38.78M, with a low forecast of $38.78M, and a high forecast of $38.78M. ADPT's average Quarter revenue forecast represents a -15.31% decrease compared to the company's last Quarter revenue of $45.78M (Dec 23).

Adaptive Bio EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	5	4	4	4	5	8	5	4	4	3	4	3	5	4	5	4	5	4	5	4	4	3
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$-40.25M	$-50.96M	$-47.82M	$-48.75M	$-36.16M	$-39.28M	$-47.31M	$-58.01M	$-56.49M	$-52.47M	$-46.40M	$-37.97M	$-41.10M	$-33.89M	$-33.02M	$-29.75M	$-18.54M	$-11.89M
Avg Forecast	$-63.47M	$-58.20M	$-56.57M	$-50.40M	$-54.69M	$-51.64M	$-49.27M	$-44.22M	$-43.72M	$-38.11M	$-36.60M	$-72.56M	$-45.90M	$-40.70M	$-42.51M	$-65.96M	$-62.14M	$-46.87M	$-40.99M	$-59.97M	$-35.65M	$-35.91M	$-30.65M	$-49.08M	$-26.36M	$-23.13M	$-18.43M	$-22.31M	$-21.29M	$-21.66M
High Forecast	$-59.91M	$-54.94M	$-53.40M	$-47.58M	$-51.63M	$-48.75M	$-46.51M	$-42.74M	$-41.02M	$-38.07M	$-36.60M	$-58.05M	$-41.82M	$-38.74M	$-40.13M	$-52.77M	$-49.71M	$-46.87M	$-40.99M	$-47.97M	$-35.65M	$-35.91M	$-30.65M	$-39.27M	$-26.36M	$-23.13M	$-18.43M	$-17.85M	$-21.29M	$-21.66M
Low Forecast	$-66.24M	$-60.74M	$-59.04M	$-52.61M	$-57.09M	$-53.90M	$-51.43M	$-45.77M	$-45.18M	$-38.15M	$-36.60M	$-87.07M	$-55.83M	$-44.52M	$-44.37M	$-79.16M	$-74.57M	$-46.87M	$-40.99M	$-71.96M	$-35.65M	$-35.91M	$-30.65M	$-58.90M	$-26.36M	$-23.13M	$-18.43M	$-26.77M	$-21.29M	$-21.66M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.88%	1.25%	1.12%	0.74%	0.58%	0.84%	1.15%	0.97%	1.58%	1.46%	1.51%	0.77%	1.56%	1.47%	1.79%	1.33%	0.87%	0.55%

undefined analysts predict ADPT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Adaptive Bio's previous annual EBITDA (undefined) of $NaN.

Adaptive Bio Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	5	4	4	4	5	8	5	4	4	3	4	3	5	4	5	4	5	4	5	4	4	3
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-69.44M	$-50.30M	$-47.81M	$-61.74M	$-24.52M	$-45.17M	$-51.63M	$-62.52M	$-61.34M	$-56.00M	$-49.30M	$-40.64M	$-44.57M	$-36.72M	$-33.53M	$-31.40M	$-20.61M	$-13.95M
Avg Forecast	$-20.65M	$-21.39M	$-25.82M	$-35.40M	$-31.17M	$-32.70M	$-35.42M	$-40.66M	$-37.80M	$-42.42M	$-49.28M	$-79.29M	$-48.87M	$-49.96M	$-51.16M	$-72.08M	$-67.47M	$-53.51M	$-63.14M	$-65.53M	$-66.64M	$-62.10M	$-61.22M	$-52.54M	$-43.25M	$-41.46M	$-41.52M	$-23.55M	$-29.17M	$-36.56M
High Forecast	$-19.15M	$-19.83M	$-23.94M	$-32.83M	$-28.90M	$-30.31M	$-32.84M	$-37.54M	$-33.44M	$-39.33M	$-45.69M	$-63.43M	$-45.82M	$-33.80M	$-47.44M	$-57.66M	$-53.98M	$-53.51M	$-63.14M	$-52.42M	$-66.64M	$-62.10M	$-61.22M	$-42.03M	$-43.25M	$-41.46M	$-41.52M	$-18.84M	$-29.17M	$-36.56M
Low Forecast	$-21.83M	$-22.61M	$-27.28M	$-37.42M	$-32.95M	$-34.56M	$-37.43M	$-45.36M	$-42.16M	$-44.83M	$-52.09M	$-95.14M	$-53.46M	$-54.37M	$-54.08M	$-86.49M	$-80.97M	$-53.51M	$-63.14M	$-78.63M	$-66.64M	$-62.10M	$-61.22M	$-63.04M	$-43.25M	$-41.46M	$-41.52M	$-28.26M	$-29.17M	$-36.56M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.42%	1.01%	0.93%	0.86%	0.36%	0.84%	0.82%	0.95%	0.92%	0.90%	0.81%	0.77%	1.03%	0.89%	0.81%	1.33%	0.71%	0.38%

Adaptive Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ADPT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Adaptive Bio SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	5	4	4	4	5	8	5	4	4	3	4	3	5	4	5	4	5	4	5	4	4	3
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$42.63M	$40.57M	$46.17M	$43.14M	$46.14M	$42.27M	$45.48M	$50.24M	$50.04M	$45.10M	$39.28M	$35.54M	$31.94M	$26.55M	$26.57M	$25.83M	$20.83M	$17.58M
Avg Forecast	$67.59M	$61.97M	$60.24M	$53.67M	$58.24M	$54.99M	$52.47M	$47.09M	$46.56M	$40.59M	$38.97M	$39.12M	$48.88M	$43.34M	$45.27M	$37.13M	$55.20M	$48.23M	$42.17M	$38.10M	$36.69M	$36.95M	$31.54M	$27.96M	$27.12M	$23.80M	$18.96M	$19.37M	$21.90M	$22.29M
High Forecast	$70.54M	$64.68M	$62.87M	$56.02M	$60.79M	$57.39M	$54.77M	$48.74M	$48.11M	$40.63M	$38.97M	$39.12M	$59.45M	$47.41M	$47.25M	$38.76M	$57.62M	$48.23M	$42.17M	$38.10M	$36.69M	$36.95M	$31.54M	$27.96M	$27.12M	$23.80M	$18.96M	$23.25M	$21.90M	$22.29M
Low Forecast	$63.80M	$58.50M	$56.86M	$50.66M	$54.98M	$51.91M	$49.53M	$45.51M	$43.69M	$40.55M	$38.97M	$39.12M	$44.54M	$41.26M	$42.73M	$35.05M	$52.11M	$48.23M	$42.17M	$38.10M	$36.69M	$36.95M	$31.54M	$27.96M	$27.12M	$23.80M	$18.96M	$15.50M	$21.90M	$22.29M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.87%	0.94%	1.02%	1.16%	0.84%	0.88%	1.08%	1.32%	1.36%	1.22%	1.25%	1.27%	1.18%	1.12%	1.40%	1.33%	0.95%	0.79%

Adaptive Bio's average Quarter SG&A projection for Mar 24 is $39.12M, based on 4 Wall Street analysts, with a range of $39.12M to $39.12M. The forecast indicates a -8.25% fall compared to ADPT last annual SG&A of $42.63M (Dec 23).

Adaptive Bio EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	5	4	4	4	5	8	5	4	4	3	4	3	5	4	5	4	5	4	5	4	4	3
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$-0.48	$-0.35	$-0.33	$-0.43	$-0.17	$-0.32	$-0.36	$-0.44	$-0.43	$-0.40	$-0.35	$-0.29	$-0.33	$-0.27	$-0.26	$-0.25	$-0.17	$-0.11
Avg Forecast	$-0.14	$-0.14	$-0.17	$-0.24	$-0.21	$-0.22	$-0.24	$-0.28	$-0.26	$-0.29	$-0.33	$-0.35	$-0.33	$-0.34	$-0.35	$-0.38	$-0.35	$-0.36	$-0.43	$-0.45	$-0.45	$-0.42	$-0.42	$-0.40	$-0.29	$-0.28	$-0.28	$-0.21	$-0.20	$-0.25
High Forecast	$-0.13	$-0.13	$-0.16	$-0.22	$-0.20	$-0.21	$-0.22	$-0.25	$-0.23	$-0.27	$-0.31	$-0.32	$-0.31	$-0.23	$-0.32	$-0.35	$-0.32	$-0.36	$-0.43	$-0.45	$-0.45	$-0.42	$-0.42	$-0.40	$-0.29	$-0.28	$-0.28	$-0.21	$-0.20	$-0.25
Low Forecast	$-0.15	$-0.15	$-0.18	$-0.25	$-0.22	$-0.23	$-0.25	$-0.31	$-0.29	$-0.30	$-0.35	$-0.37	$-0.36	$-0.37	$-0.37	$-0.40	$-0.37	$-0.36	$-0.43	$-0.45	$-0.45	$-0.42	$-0.42	$-0.40	$-0.29	$-0.28	$-0.28	$-0.21	$-0.20	$-0.25
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.45%	1.03%	0.95%	1.14%	0.49%	0.88%	0.84%	0.97%	0.95%	0.95%	0.84%	0.72%	1.12%	0.96%	0.92%	1.20%	0.86%	0.44%

According to undefined Wall Street analysts, Adaptive Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ADPT previous annual EPS of $NaN (undefined).

Adaptive Bio Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HEPA	Hepion Pharmaceuticals	$0.69	$70.00	10044.93%	Buy
ELEV	Elevation Oncology	$0.61	$9.00	1375.41%	Buy
KNTE	Kinnate Biopharma	$2.65	$30.00	1032.08%	Hold
VERV	Verve Therapeutics	$4.60	$19.00	313.04%	Buy
VIR	Vir Bio	$6.95	$26.60	282.73%	Buy
ZURA	Zura Bio	$2.93	$10.00	241.30%	Buy
SANA	Sana Bio	$2.35	$8.00	240.43%	Buy
ADPT	Adaptive Bio	$4.37	$12.33	182.15%	Hold
APLS	Apellis Pharmaceuticals	$27.75	$74.50	168.47%	Buy
BEAM	Beam Therapeutics	$23.58	$58.50	148.09%	Buy
LEGN	Legend Biotech	$39.75	$82.69	108.03%	Buy
RPRX	Royalty Pharma	$26.40	$43.33	64.13%	Buy
CRBU	Caribou Biosciences	$1.98	$3.00	51.52%	Buy
VECT	VectivBio	$16.87	$18.00	6.70%	Buy
KRYS	Krystal Biotech	$182.29	$191.00	4.78%	Buy
RPHM	Reneo Pharmaceuticals	$18.20	$18.00	-1.10%	Buy
IKNA	Ikena Oncology	$1.73	$1.33	-23.12%	Buy

ADPT Forecast FAQ

Is Adaptive Bio a good buy?

No, according to 12 Wall Street analysts, Adaptive Bio (ADPT) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 33.33% of ADPT's total ratings.

What is ADPT's price target?

Adaptive Bio (ADPT) average price target is $12.33 with a range of $5 to $18, implying a 182.15% from its last price of $4.37. The data is based on 12 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Adaptive Bio stock go up soon?

According to Wall Street analysts' prediction for ADPT stock, the company can go up by 182.15% (from the last price of $4.37 to the average price target of $12.33), up by 311.90% based on the highest stock price target, and up by 14.42% based on the lowest stock price target.

Can Adaptive Bio stock reach $7?

ADPT's average twelve months analyst stock price target of $12.33 supports the claim that Adaptive Bio can reach $7 in the near future.

What are Adaptive Bio's analysts' financial forecasts?

Adaptive Bio's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $210.95M (high $219.77M, low $200.18M), average EBITDA is $-200M (high $-190M, low $-208M), average net income is $-140M (high $-130M, low $-150M), average SG&A $212.8M (high $221.69M, low $201.93M), and average EPS is $-0.949 (high $-0.879, low $-1.019). ADPT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $241.36M (high $251.92M, low $227.84M), average EBITDA is $-229M (high $-216M, low $-239M), average net income is $-103M (high $-95.744M, low $-109M), average SG&A $243.47M (high $254.12M, low $229.83M), and average EPS is $-0.7 (high $-0.649, low $-0.74).

Did the ADPT's actual financial results beat the analysts' financial forecasts?

Based on Adaptive Bio's last annual report (Dec 2023), the company's revenue was $170.28M, which missed the average analysts forecast of $173.1M by -1.63%. Apple's EBITDA was $-179M, missing the average prediction of $-195M by -8.04%. The company's net income was $-225M, beating the average estimation of $-222M by 1.43%. Apple's SG&A was $172.51M, missing the average forecast of $174.61M by -1.20%. Lastly, the company's EPS was $-1.56, beating the average prediction of $-1.394 by 11.92%. In terms of the last quarterly report (Dec 2023), Adaptive Bio's revenue was $45.78M, missing the average analysts' forecast of $48.45M by -5.51%. The company's EBITDA was $-40.247M, missing the average prediction of $-45.898M by -12.31%. Adaptive Bio's net income was $-69.441M, beating the average estimation of $-48.874M by 42.08%. The company's SG&A was $42.63M, missing the average forecast of $48.88M by -12.77%. Lastly, the company's EPS was $-0.48, beating the average prediction of $-0.331 by 44.88%